These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

975 related items for PubMed ID: 12538485

  • 1. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.
    Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM.
    Clin Cancer Res; 2003 Jan; 9(1):327-37. PubMed ID: 12538485
    [Abstract] [Full Text] [Related]

  • 2. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248.
    Potapova O, Laird AD, Nannini MA, Barone A, Li G, Moss KG, Cherrington JM, Mendel DB.
    Mol Cancer Ther; 2006 May; 5(5):1280-9. PubMed ID: 16731761
    [Abstract] [Full Text] [Related]

  • 3. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.
    Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM.
    Mol Cancer Ther; 2003 May; 2(5):471-8. PubMed ID: 12748309
    [Abstract] [Full Text] [Related]

  • 4. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.
    O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM.
    Blood; 2003 May 01; 101(9):3597-605. PubMed ID: 12531805
    [Abstract] [Full Text] [Related]

  • 5. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
    Laird AD, Vajkoczy P, Shawver LK, Thurnher A, Liang C, Mohammadi M, Schlessinger J, Ullrich A, Hubbard SR, Blake RA, Fong TA, Strawn LM, Sun L, Tang C, Hawtin R, Tang F, Shenoy N, Hirth KP, McMahon G, Cherrington.
    Cancer Res; 2000 Aug 01; 60(15):4152-60. PubMed ID: 10945623
    [Abstract] [Full Text] [Related]

  • 6. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.
    Cancer Res; 2003 Sep 15; 63(18):5978-91. PubMed ID: 14522925
    [Abstract] [Full Text] [Related]

  • 7. SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice.
    Laird AD, Christensen JG, Li G, Carver J, Smith K, Xin X, Moss KG, Louie SG, Mendel DB, Cherrington JM.
    FASEB J; 2002 May 15; 16(7):681-90. PubMed ID: 11978732
    [Abstract] [Full Text] [Related]

  • 8. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer.
    Abrams TJ, Murray LJ, Pesenti E, Holway VW, Colombo T, Lee LB, Cherrington JM, Pryer NK.
    Mol Cancer Ther; 2003 Oct 15; 2(10):1011-21. PubMed ID: 14578466
    [Abstract] [Full Text] [Related]

  • 9. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function.
    Mendel DB, Schreck RE, West DC, Li G, Strawn LM, Tanciongco SS, Vasile S, Shawver LK, Cherrington JM.
    Clin Cancer Res; 2000 Dec 15; 6(12):4848-58. PubMed ID: 11156244
    [Abstract] [Full Text] [Related]

  • 10. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G.
    Cancer Res; 2004 Jul 15; 64(14):4931-41. PubMed ID: 15256466
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis.
    Haspel HC, Scicli GM, McMahon G, Scicli AG.
    Microvasc Res; 2002 May 15; 63(3):304-15. PubMed ID: 11969307
    [Abstract] [Full Text] [Related]

  • 12. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.
    Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI.
    J Clin Oncol; 2006 Jan 01; 24(1):16-24. PubMed ID: 16330672
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans.
    Moss KG, Toner GC, Cherrington JM, Mendel DB, Laird AD.
    J Pharmacol Exp Ther; 2003 Nov 01; 307(2):476-80. PubMed ID: 12966161
    [Abstract] [Full Text] [Related]

  • 17. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.
    O'Farrell AM, Foran JM, Fiedler W, Serve H, Paquette RL, Cooper MA, Yuen HA, Louie SG, Kim H, Nicholas S, Heinrich MC, Berdel WE, Bello C, Jacobs M, Scigalla P, Manning WC, Kelsey S, Cherrington JM.
    Clin Cancer Res; 2003 Nov 15; 9(15):5465-76. PubMed ID: 14654525
    [Abstract] [Full Text] [Related]

  • 18. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
    Amino N, Ideyama Y, Yamano M, Kuromitsu S, Tajinda K, Samizu K, Hisamichi H, Matsuhisa A, Shirasuna K, Kudoh M, Shibasaki M.
    Clin Cancer Res; 2006 Mar 01; 12(5):1630-8. PubMed ID: 16533791
    [Abstract] [Full Text] [Related]

  • 19. Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor.
    Wang D, Tang F, Wang S, Jiang Z, Zhang L.
    Cancer Chemother Pharmacol; 2012 Jan 01; 69(1):173-83. PubMed ID: 21638122
    [Abstract] [Full Text] [Related]

  • 20. Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families.
    Glaser KB, Li J, Marcotte PA, Magoc TJ, Guo J, Reuter DR, Tapang P, Wei RQ, Pease LJ, Bui MH, Chen Z, Frey RR, Johnson EF, Osterling DJ, Olson AM, Bouska JJ, Luo Y, Curtin ML, Donawho CK, Michaelides MR, Tse C, Davidsen SK, Albert DH.
    J Pharmacol Exp Ther; 2012 Dec 01; 343(3):617-27. PubMed ID: 22935731
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.